What is IMMX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.78B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMMX?

P/E (TTM) is n/a and 52-week range is $2.31 to $15.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMMX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMMX?

The company profile lists net income (TTM) near $-60M, EPS (TTM) near $-0.87 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Immix Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Los Angeles, California, US, 69.8M shares outstanding, ISIN US45258H1068 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Immix Biopharma Inc

$IMMX

Health Care · Biotechnology

IR Run Scenarios

$9.46

+1.83%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 21 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Employees

Website

immixbio.com/

IPO

2021-12-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)